
Opinion|Videos|September 11, 2024
Understanding Oligometastatic Disease in Prostate Cancer: Insights from PSMA PET Imaging
Author(s)Jaideep S. Sohi, MD, Jeremie Calais, MD
Key opinion leaders examine the role of advanced imaging agents, particularly PSMA PET and other radiotracers, in identifying and defining oligometastatic disease in patients with prostate cancer.
Advertisement
Video content above is prompted by the following:
- How do imaging agents, such as PSMA PET or other radiotracers, contribute to the detection and characterization of oligometastasis in prostate cancer patients?
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
Leading Breast Radiologists Discuss the Recent Lancet Study on AI and Interval Breast Cancer
2
Is AI Better Than Neuroradiologists at Evaluating Aneurysm Growth on CTA and MRA Scans?
3
FDA Clears AI-Powered Triage Platform for Digital Breast Tomosynthesis
4
Study Shows Photon-Counting CT Reduces Radiation Exposure by 66 Percent for Patients with Lung Cancer
5











